HIV

HIV positive patients coinfected with hepatitis may face elevated cancer risk.

A cell-editing platform allowed researchers to find genetic mutations that allow human immune cells to be resistant to HIV.

Descovy showed non-inferiority to Truvada, and benefited bone and kidney health.

Ibalizumab for multi-drug resistant HIV showed significant promise fighting the disease.

HIV has been an epidemic for 30 years. Initially, the health system relied on behavioral interventions to slow the spread of the virus.

Ibalizumab achieves primary endpoint in decreasing the viral load of patients with drug-resistant HIV.

Ibalizumab caused 83% of HIV-positive patients to achieve a virologic response.

An automated algorithm was able to select HIV-positive individuals who would benefit the most from PrEP.

Dolutegravir/abacavir shows a solid safety profile and a high barrier to resistance.

Researchers seek to improve HIV drug therapies through nanomedicine.

Monkeys infected with SIV were successfully able to suppress SIV even without antiretroviral therapy.

Top news of the day from across the health care landscape.

Mathematical models and prevention techniques assess viral suppression among HIV-positive men who have sex with men.

Pseudomonas aeruginosa causes infections in patients with HIV, cancer, and other immune-compromised disease states.

Researchers examine strategies to control the spread of HIV.

Researchers created a technique that targets HIV reservoirs.

A small proportion of HIV-infected children do not develop AIDS by controlling the virus in a different way than infected adults who remain disease-free.

Broad-spectrum HIV-targeting monoclonal antibodies may lead to a cure for HIV in the future.

Evidence-based treatment for depression and adherence counseling could boost HIV treatment.

Successful highly active antiretroviral therapy (HAART) has allowed the long-term effects of HIV infection and chronic medication toxicity to become the primary cause of death and disability. However, HIV-positive patients are at greater risk for cardiovascular disease and cancers due to excessive inflammation, and HAART does not eliminate HIV-related inflammation even if the patient adheres to treatment perfectly.

HIV compromises the immune system, making patients more susceptible to tuberculosis.

T cell subset may play a crucial role in the development of diabetes.

Top news of the day from across the healthcare landscape.

Top news of the day from across the health care landscape.

Coinfection with HIV plus a hepatitis B, C, or both, adds to the risk of non-Hodgkins lymphoma.

Top news of the day from across the health care landscape.

Mytesi is the only FDA approved treatment for noninfectious diarrhea in HIV positive patients.

Study highlights care strategies for HIV patients to address the differences in the disease among patients in different age groups.

Limited evidence connects HIV severity and highly active antiretroviral therapy (HAART) regimens.

HIV-positive patients experience sudden death more often than the general population, but scant evidence connects HIV severity and highly active antiretroviral therapy regimens.